NRSN
NeuroSenseยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
NRSN Profile
Neurosense Therapeutics Ltd.
A company that developing treatments for severe neurodegenerative diseases
Biological Technology
02/13/2017
12/09/2021
NASDAQ Stock Exchange
15
12-31
Common stock
11 HaMenofim Street, Building B, Herzliya 4672562 Israel
--
NeuroSense Therapeutics Ltd. was incorporated in Israel on February 13, 2017. The company is a clinical-stage biotechnology company focused on discovering and developing treatments for patients with neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead therapeutic candidate, PrimeC, is a novel sustained-release oral formulation consisting of a fixed-dose combination of two FDA-approved drugs, ciprofloxacin and celecoxib. PrimeC is designed to treat ALS by regulating microRNA synthesis, iron accumulation, and neuroinflammation, all of which are hallmarks of ALS pathology.
